Prognostic parameters in recurrent malignant melanoma

Area of Science:

• Oncology
• Dermatology
• Medical Statistics

Background:

• Recurrent malignant melanoma presents a significant challenge in patient management.
• Identifying prognostic factors is crucial for predicting survival outcomes in melanoma patients.
• Understanding determinants of survival aids in tailoring treatment strategies for melanoma recurrence.

Purpose of the Study:

• To identify the strongest determinants of survival in patients with recurrent malignant melanoma.
• To investigate the impact of clinical stage, number of metastatic lesions, and disease-free interval on survival.
• To analyze how age and sex influence disease-free interval and survival post-recurrence.

Main Methods:

• Retrospective analysis of clinical data from 361 patients with recurrent malignant melanoma.
• Statistical evaluation of the correlation between clinical stage, initial lesion count, disease-free interval, age, sex, and survival.
• Kaplan-Meier survival analysis and log-rank tests were employed to assess significance.

Main Results:

• Clinical stage was the most significant predictor of survival (P < 0.01).
• In Stage IV, patients with a single metastatic nodule had a median survival of 10 months versus 6.9 months for those with multiple nodules (P < 0.05).
• A disease-free interval (DFI) of one year or longer correlated with improved survival (median 23.7 months, 30% 5-year survival) compared to DFI < 1 year (median 15.8 months, 16% 5-year survival) in regional lymph node metastases (P < 0.05). For Stage IV, DFI > 24 months became significant.
• Age and sex influenced DFI but not survival after recurrence.

Conclusions:

• Clinical stage is the paramount prognostic factor for recurrent malignant melanoma.
• The number of initial metastatic lesions and the length of the disease-free interval are critical for survival, particularly in Stage IV disease.
• Prognostic models should incorporate these factors to better predict outcomes for melanoma recurrence.